Feedback PLC Bleepa adds 3D Imaging with Axial3D Partnership (5367C)
October 20 2020 - 1:00AM
UK Regulatory
TIDMFDBK
RNS Number : 5367C
Feedback PLC
20 October 2020
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 ("MAR"). With the publication of this announcement,
this information is now considered to be in the public domain.
Feedback plc
Bleepa adds 3D imaging through partnership with Axial3D
-- Enables clinicians to view and manipulate 3D clinical medical
images to support clinical decision making and surgical
planning
-- Supports 3D model printing
-- Suitable for complex surgical planning, patient education and
consent and clinician training
London, 20 October 2020: Feedback plc (AIM: FDBK, "Feedback" or
the "Company"), the specialist medical imaging technology company,
today announces a commercial partnership with Axial Medical
Printing Limited (trading as Axial3D (www.axial3d.com)) to enable
the visualisation and use of 3D clinical-grade medical images from
a patient's own 2D scan through Feedback's flagship medical imaging
communications platform, Bleepa.
Axial3D uses advanced AI technologies to automatically segment
imaging data and pull out isolated 3D reconstructions of individual
organs or pathologies. These images will be available to view in
the Bleepa platform and if required, can subsequently be turned
into 3D printed models in a variety of materials. Axial3D's AI
imaging technology will be integrated with Bleepa to enable the
movement of users and DICOM (the standard format for medical
images) between the two platforms, leveraging Bleepa's digital
modular design to provide clinicians with 3D rendered images of
specific pathologies or organs. By partnering, frontline clinicians
will be able to request Axial3D image renders from within Bleepa.
The Bleepa user will be able to click through to Axial3D's system
from Bleepa and the supporting DICOM study will be automatically
pushed by Bleepa to Axial3D. Axial3D will enter into its own
commercial relationship with customers, but Bleepa will act as the
user access point and will facilitate the data transfer on its
behalf, with the customer's permission and following the agreed
data processing arrangements between the customer and Axial3D.
Increasingly, clinicians are looking to 3D imaging and 3D
printed models of anatomical areas, created exactly from patients'
2D scans, which can be held in-hand and used for preoperative
planning, simulation and collaborative team working. These
anatomical images and models are often used in patient
communication and consultation to show and explain to patients
their medical conditions and what their surgical procedures will
involve. 3D anatomical models also have use in surgical education,
providing medical students and junior doctors the opportunity to
exactly see tumours, fractures, lesions and other
abnormalities.
The commercial agreement will enable joint- and cross-selling of
both products through each company's distribution channels to new
and existing customers, enabling both organisations to grow
collaboratively. Under the agreement Feedback will receive a
commission for each user-generated image request from Axial3D. This
is the first example of the Company's strategy to leverage its
growing userbase to generate supplementary revenue, over and above
the main user licence fee.
Dr Tom Oakley, CEO of Feedback, commented:
"The addition of 3D imaging and printing enhances our value
proposition to Bleepa users and re-enforces our vision to bring
clinicians together, armed with the tools and information they need
to make better informed decisions faster. We are delighted to have
Axial3D as such a dynamic and cutting-edge partner who share our
vision and passion for supporting frontline clinicians. We hope
that Bleepa will make Axial's technology even more accessible to a
wider clinical userbase and that our partnership will help to drive
the adoption of this key technology into the mainstream of
frontline care. This important milestone confirms our strategy of
becoming a gatekeeper platform for third-party technologies in
order to generate additional revenues beyond the Bleepa user
licence. We hope that this will be the first of many such
partnerships."
Roger Johnston, CEO of Axial3D, said:
"At Axial3D, we believe that the introduction of 3D imaging for
planning complex surgeries can transform outcomes for patients,
surgical teams and indeed hospitals. When surgeons use our models
for surgical planning they tell us that in over 53% of cases they
change their plan for surgery, compared to relying solely on the 2D
MRI/CT scans. This leads to shorter surgeries, reduced costs of
surgeries, reduced risk of patient infection with often less
traumatic surgery, thus often leading to a shorter stay in
hospital. Bleepa allows us to make available 3D imaging available
as standard for clinical teams who are planning the surgeries,
engaging with patients and their families, through to the surgeries
themselves. We believe that Bleepa will transform surgical team
collaboration across the NHS and beyond and Axial3D is delighted to
be going on that journey with such a game-changing partner."
-Ends-
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Lindsay Melvin, CFO
Allenby Capital Limited (Nominated
Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Capital Limited (Joint
Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited
(Joint Broker)
Patrick Claridge / John Howes +44 20 3815 8880
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas 07980 541 893 or 07748 325 236 or
Johnson 07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a medical imaging technology
business. Its core product, Bleepa, is a revolutionary medical
imaging communications app, providing an easy-to-use, high quality
tool to enable remote and secure communications between front-line
clinicians and teams. Importantly, it is the only CE marked medical
imaging communications platform on the NHSx clinical communications
tools framework. Bleepa has unparalleled functionality for everyday
practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS")-based revenue
model will provide increasing levels of visibility as the Company
grows its customer base. With a growing distribution base and
technology in place, the focus is on leveraging key relationships
in order to drive sales both in the UK and internationally to all
forms of care facilitators. As a fully certified medical device,
Bleepa aims to disrupt the medical imaging communications market
and, importantly, increase the accuracy and speed of diagnosis.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRUKVNRRUURAAA
(END) Dow Jones Newswires
October 20, 2020 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2023 to Apr 2024